AIDS 2022 logo

The 24th International AIDS Conference

AIDS 2022 will take place from 29 July to 2 August 2022, with pre-conference meetings beginning on 27 July 2022.

The 24th International AIDS Conference (AIDS 2022) is the world’s largest conference on HIV and AIDS will be hosted in person in Montreal, Canada, as well as virtually. AIDS 2022 will call on the world to come together to re-engage and follow the science. It will define future research agendas, shift latest evidence to action, and chart a new consensus on overcoming the HIV epidemic as a threat to public health and individual well-being.

Listed below are AIDS 2022 sessions, symposia, and satellites affiliated with the HIV/AIDS Clinical Trials Networks. Session presenters marked with an asterisk (*) are affiliated with the HIV/AIDS Clinical Trials Networks. 

All sessions are listed in Eastern Daylight Time (EDT), UTC-4.

 

More sessions will be added to this page as information becomes available. Please check back closer to the conference dates for a complete listing of HIV/AIDS Clinical Trials Network sessions

Preconference Events

Interfaith Preconference: Taking action to overcome HIV Stigma and Discrimination

Preconference Event, Montreal's La Plaza Centre-Ville-EVO

International Workshop on HIV & Pediatrics

Workshop, Sofitel Montreal Golden Mile

Associated Protocols Abstract Title Presenting Author Format
PROMISE P1084s Changes in bone turnover markers after delivery in breastfeeding mothers with and without ARVs Kristin Baltrusaitis Oral session

Friday, July 29

Oral Abstract Session, OALBX01

11:45
2 min
Introduction
Jean-Pierre Routy, Canada
Adeeba Kamarulzaman, Malaysia
11:47
8 min
Transcriptional programs of HIV silencing and cell survival in HIV-infected memory CD4 T cells under antiretroviral therapy
Eli Boritz, Vaccine Research Center, NIAID, NIH USA, United States
11:55
8 min
Doxycycline post-exposure prophylaxis for STI prevention among MSM and transgender women on HIV PrEP or living with HIV: high efficacy to reduce incident STI's in a randomized trial
Annie Luetkemeyer, Zuckerberg San Francisco General Hospital, UCSF, United States
12:03
8 min
Week 48 results of a Phase 3 randomized controlled trial of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) vs dolutegravir + emtricitabine/tenofovir Disoproxil Fumarate (DTG+F/TDF) as initial treatment in HIV/HBV-coinfected adults (ALLIANCE)
Anchalee Avihingsanon, HIV-NAT, Thai Red Cross AIDS Research Centre, Thailand
12:11
8 min
Trends in PrEP inequity by race and census region, United States, 2012-2021
Patrick Sullivan, Emory University, United States
12:19
8 min
Long acting cabotegravir: updated efficacy and safety results from HPTN 084
*Sinead Delany-Moretlwe, University of Witwatersrand, South Africa
12:27
13 min
Q&A
Adeeba Kamarulzaman, Malaysia
Jean-Pierre Routy, Canada
Anchalee Avihingsanon, HIV-NAT, THai Red Cross AIDS Research Centre, Thailand
*Sinead Delany-Moretlwe, University of the Witwatersrand, South Africa
Eli Boritz, Vaccine Research Center, NIAID, NIH USA, United States
Annie Luetkemeyer, Zuckerberg San Francsico General Hospital, UCSF, United States
Patrick Sullivan, Emory University, United States
12:40
5 min
IAS President's Award
Adeeba Kamarulzaman, Malaysia
Soumya Swaminathan

Satellite Session, SA023

14:45
10 min
Experimental Medicine Vaccine Trials
Robin Shattock, Imperial College, United Kingdom
14:55
10 min
Status of HIV Vaccine Research
Kundai Chinyenze, International AIDS Vaccine Initiative (IAVI), Kenya
15:05
10 min
Experimental Medicine Vaccine Trials: community considerations, questions and perspectives
Ntando Yola, Desmond Tutu HIV Foundation (DTHF), South Africa
15:15
45 min
Panel Discussion
Cathy Slack, HIV/AIDS Vaccine Ethics Group (HAVEG), South Africa
Pervin Anklesaria, Bill & Melinda Gates Foundation (BMGF), United States
Eunice Nduati, KEMRI Wellcome Trust Research Programme, Kenya
Mary Marovich, National Institutes of Health (NIH), United States
Maureen Luba, Global Advocacy for HIV Prevention (AVAC), Malawi
*Nyaradzo Mavis Mgodi, University of Zimbabwe, Zimbabwe

Satellite Session, SA024

14:45
10 min
Official launch of JIAS Supplement and overview of the framework to enhance and accelerate the study of new HIV drugs in pregnancy
Annette Sohn, amfAR, the Foundation for AIDS Research, Thailand
Martina Penazzato, WHO HQ, Switzerland
*Elaine Abrams, IMPAACT Network & ICAP at Columbia University, United States
14:55
25 min
Panel 1: Keeping momentum and generating tangible progress in accelerating research in pregnancy
*Sinead Delany-Moretlwe, University of the Witwatersrand, South Africa
Nahida Chakhtoura, The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), United States
Annemiek De Ruiter, ViiV Healthcare, United Kingdom
Saye Khoo, University of Liverpool, United Kingdom
Carmen Perez Casas, Unitaid, SwitzerlandLeyla SAHIN, U.S. Food and Drug Administration (FDA), United States
15:20
25 min
Effective and meaningful support of participants in research
Imelda Chipo Mahaka, Pangaea Zimbabwe AIDS Trust, Zimbabwe
Mercy Shibemba, Penta Foundation, United Kingdom
15:45
25 min
Panel 2: Amplifying impact by joining forces across disease areas to study new drugs during pregnancy
Amita Gupta, Johns Hopkins Bloomberg School of Public Health, United States
Carmen Perez Casas, Unitaid, Switzerland
Myriam El-Gaaloul, Medicines for Malaria Venture, Switzerland
Manal El-Sayed, Ain Shams University, Egypt
Melanie Taylor, Centers for Disease Control and Prevention, United States
16:10
5 min
Bringing it all together: charting the path towards more equitable access to novel therapeutics
Meg Doherty, World Health Organization, Switzerland
*Sharon Nachman, IMPAACT Network & Stony Brook University Hospital, United States

Satellite Session, SA041

18:15
2 min
Introduction and welcome 
Nelli Barrière, International AIDS Society, Switzerland
18:17
10 min
Role of the pharmaceutical industry in HIV prevention and vaccine research - A researcher's perspective
*Linda-Gail Bekker, Desmond Tutu HIV Centre, South Africa
18:27
10 min
Importance of community engagement with the pharmaceutical industry for HIV prevention research - A community perspective
18:37
10 min
What does a successful public-private partnership for HIV vaccine R&D look like?
*Dan Barouch, Center for Virology and Vaccine Research, BIDMC, United Statess
18:47
15 min
IAS Global HIV Vaccine Enterprise Industry Partnership launch
Birgit Poniatowski, International AIDS Society (IAS), Switzerland
19:02
40 min
Panel discussion
*Shan Lu, Worcester HIV Vaccine, United States
19:42
3 min
Closing

Saturday, July 30


Satellite Session, SA046

8:00
5 min
Introduction: On a reinvigorated HIV vaccine R&D fields and the promises and challenges of mRNA as a platform for the development of an HIV vaccine.
*Susan Buchbinder, San Francisco Department of Public Heath, United States
8:05
8 min
IAVI/Moderna studies (G001,G002,G003)
*Bill Schief, Scripps Research / IAVI's Neutralizing Antibody Center (NAC), United States
8:13
8 min
HVTN 302
*Sharon Riddler, University of Pittsburgh, United States
8:21
8 min
Differences in developing a vaccine for HIV vs. COVID
*Georgia Tomaras, Duke Human Vaccine Institute, United States
8:29
30 min
Panel discussion
*Susan Barnett, Bill & Melinda Gates Foundation, United States
Julien Nyombayire Zambia Health Research Group - Projet San Francisco/Center for Family Health Research, Rwanda
*Ntando Yola, Desmond Tutu HIV Foundation (DTHF), South Africa

Oral Abstract Session, OALBA01

11:45
2 min
Introduction
Brad Jones, Weill Cornell Medicine, United States
11:47
8 min
Immune correlates analysis of the Imbokodo HIV-1 vaccine efficacy trial
*Avi Kenny, Department of Biostatistics, University of Washington, United States
11:55
8 min
FIt3 agonist enhances immunogenicity of arenavirus-vector based vaccines in macaques
Brie Falkard, Gilead Sciences, Inc, United States
12:03
8 min
Metabolomic and lipidomic correlates of time-to-HIV-rebound in viremic controllers treated with vesatolimod 
Yanhui Cai, Gilead Sciences, United States
12:11
34 min
Q&A
Brad Jones, Weill Cornell Medicine, United States
Yanhui Cai, Gilead Sciences, United States
*Avi Kenny, Department of Biostatistics, University of Washington, United States
Brie Falkard, Gilead Sciences, Inc, United States

Global Village Session Presentation with Q&A, GVSY06

Sunday, July 31


Prime Session, PR04

9:15
3 min
Introduction
Jerome Kim, International Vaccine Institute (IVI), Korea, Republic of
Diana Finzi, National Institutes of Health, United States
9:18
15 min
In pursuit of an HIV vaccine
*Glenda Gray, South African Medical Research Council, South Africa
9:33
15 min
Immunotherapies towards an HIV cure
Thomas Aagaard Rasmussen, Aarhus University Hospital, Denmark
9:48
17 min
Q&A
Jerome Kim, International Vaccine Institute (IVI), Korea, Republic of
Diana Finzi, National Institutes of Health, United States
*Glenda Gray, South African Medical Research Council, South Africa
10:05
2 min
Closing remarks
Jerome Kim, International Vaccine Institute (IVI), Korea, Republic of
Diana Finzi, National Institutes of Health, United States
10:07
8 min
IAS CPP Research-for-Cure Academy Fellowship

Oral Abstract Session, OAB01

10:30
2 min
Introduction
Tonia Poteat, University of North Carolina, United States
10:32
8 min
Chronic injection opioid use increases the systemic inflammation and T cell immune activation in virally suppressed people living with HIV
Christine Dang, University of Miami, United States
10:40
8 min
Impact of gender identity- and HIV-related stigmas and psychosocial resources on mental health and alcohol use among transgender women newly diagnosed with HIV in India: a longitudinal cohort study
Viraj Patel, Albert Einstein College of Medicine, Montefiore Medical Center, United States
10:48
8 min
Forty-eight week outcomes of a combined cognitive behavioral therapy and medication management algorithm for treatment of depression among youth living with HIV in the United States (IMPAACT 2002)
*Larry Brown, Rhode Island Hospital, United States
10:56
8 min
Long-term risk of hospitalization and chronic disease among children who were HIV-exposed uninfected (cHEU) compared to population controls in Montreal, Canada
Jeanne Brochon, Hopital Sainte Justine, Canada
11:04
26 min
Q&A
Christine Dang, University of Miami, United States
Tonia Poteat, University of North Carolina, United States
Viraj Patel, Albert Einstein College of Medicine, Montefiore Medical Center, United States
*Larry Brown, Rhode Island Hospital, United States
Jeanne Brochon, Hôpital Sainte Justine, Canada

Symposium, SY21

14:15
5 min
Introductory notes on why we need to consider mAbs as a potential tool for HIV prevention
Helen Rees, Wits RHI, ECHO Committee Consortium, South Africa
14:20
10 min
Can we design, develop and manufacture antibodies that are effective, affordable and easy to deliver? Evidence from the pipeline
Devin Sok, International AIDS Vaccine Initiative, United States
14:30
45 min
Panel discussion
Rachel Baggaley, World Health Organization, Switzerland
*Lynda Stranix-Chibanda, University of Zimbabwe, Zimbabwe
Carmen Perez Casas, Unitaid, Switzerland
Sharonann Lynch, O'Neill Institute for National and Global Health Law, United States
Helen Rees, Wits RHI, ECHO Committee Consortium, South Africa
Devin Sok, International AIDS Vaccine Initiative, United States

Global Village Session Presentation with Q&A, GVSY24

Monday, August 1


Oral Abstract Session, OALBB01

11:45
2 min
Introduction
Brenda Crabtree-Ramirez, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Mexico
11:47
8 min
Phase I/II study of monoclonal antibody VRC01 with early antiretroviral therapy to promote clearance of HIV-1 infected cells in infants (IMPAACT 2008)
*Alka Khaitan, Indiana University School of Medicine, United States
11:55
8 min
Enhanced tuberculosis screening using computer-aided X-ray diagnosis and novel point of care urine lipoarabinomannan assay among adults with HIV admitted to hospital (CASTLE study): a cluster randomised trial
Rachael Burke, Malawi Liverpool Wellcome Trust, Malawi
12:03
8 min
The “City of Hope” Patient: prolonged HIV-1 remission without antiretrovirals (ART) after allogeneic hematopoietic stem cell transplantation (aHCT) of CCR5-?32/?32 donor cells for acute myelogenous leukemia (AML)
Jana Dickter, City of Hope, United States
12:11
8 min
Incident tuberculosis as a risk factor for viral non-suppression 48 weeks among patients switched to dolutegravir based therapy with recycled nucleoside reverse transcriptase inhibitors in Lusaka, Zambia
Nyuma Mbewe, University Teaching Hospital, Lusaka Zambia
12:19
26 min
Q&A
Rachael Burke, Malawi Liverpool Wellcome Trust, Malawi
Nyuma Mbewe, University Teaching Hospital, Lusaka Zambia
*Alka Khaitan, Indiana University School of Medicine, United States
Jana Dickter, City of Hope, United States
Brenda Crabtree-Ramirez, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Mexico

Symposium, SY34

14:15
2 min
Introduction
*Glenda Gray, South African Medical Research Council, South Africa
Amy Chung, The University of Melbourne, Australia
14:17
12 min
mRNA vaccine
*Barton Haynes, Duke Human Vaccine Institute and the Center for HIV-AIDS Vaccine Immunology, United States
14:29
12 min
First-in-human Phase 1 trials with SOSIP Env trimers
Godelieve de Bree, Amsterdam UMC, Netherlands
14:41
12 min
Overcoming 'improbable mutations'
*Kevin Saunders, Duke University School of Medicine, United States
14:53
12 min
bNAB infusion
*Lynn Morris, National Institute for Communicable Diseases, South Africa
15:05
10 min
Q&A
*Glenda Gray, South African Medical Research Council, South Africa
Amy Chung, The University of Melbourne, Australia
*Barton Haynes, Duke Human Vaccine Institute and the Center for HIV-AIDS Vaccine Immunology, United States
Godelieve de Bree, Amsterdam UMC, Netherlands
*Kevin Saunders, Duke University School of Medicine, United States
*Lynn Morris, National Institute for Communicable Diseases, South Africa

Oral Abstract Session, OAE03

14:15
2 min
Introduction
Viviane D. Lima, British Columbia Centre for Excellence in HIV/AIDS, Canada
14:17
8 min
The effect of a conditional cash transfer program on AIDS morbidity and mortality among the poorest: a quasi-experimental study of a cohort of 22.7 million Brazilians
Davide Rasella, Instituto de Saude Coletiva, Federal University of Bahia, Brazil
14:25
8 min
Cost-effectiveness of broadly neutralizing antibodies for HIV prophylaxis for all infants born in high-burden settings
Caitlin Dugdale, Massachusetts General Hospital, United States
14:33
8 min
The relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis: a modelled economic evaluation and threshold analysis in South Africa based on the HPTN 083 and 084 trials
*Gesine Meyer-Rath, Health and Epidemiology Research Office, University of the Witwatersrand, South Africa
14:41
8 min
Variation in average unit prices (2020) of antiretroviral drugs in generic accessible low- and middle-income countries
Deepak Mattur, UNAIDS, Switzerland
14:49
26 min
Q&A
Davide Rasella, Instituto de Saude Coletiva, Federal University of Bahia, Brazil
Caitlin Dugdale, Massachusetts General Hospital, United States
*Gesine Meyer-Rath, Health and Epidemiology Research Office, University of the Witwatersrand, South Africa
Deepak Mattur, UNAIDS, Switzerland
Viviane D. Lima, British Columbia Centre for Excellence in HIV/AIDS, Canada

Satellie Session, SA098

17:45
3 min
Introduction
*Julie Ake, U.S. Military HIV Research Program, United States
17:48
10 min
1. Better products, new platforms, new strategies: what COVID-19 has changed in HIV vaccine science
*Dan Barouch, Center for Virology and Vaccine Research, BIDMC, United States
17:58
10 min
2. What has COVID-19 changed in clinical trial management
*Fatima Laher, Director of the PHRU Vaccines Research Centre, South Africa
18:08
10 min
3. Community engagement in clinical research: Better prepared, better engaged?
18:18
10 min
5. Regulatory approval: Are we better prepared for a successful HIV vaccine?
*Helen Rees, Wits RHI, ECHO Committee Consortium, South Africa
18:25
50 min
Panel discussion-Promise held or still much more to do.

Tuesday, August 2

Satellite Session, SA105

8:00
5 min
Introduction
*Helen Ayles, Zambart, Zambia
8:05
10 min
1. Summary of PopART design and main findings
*Sarah Fidler, Imperial College London, United Kingdom
8:15
10 min
2. What have we learned from subsequent analysis to better understand our main findings and effects on TB
*Richard Hayes, London School of Hygiene and Tropical Medicine, United Kingdom
8:25
10 min
3. New data and findings including phylogenetic analysis
*Christophe Fraser, Big Data Institute, United Kingdom
8:35
10 min
4. Where do we go from here - messages for policy/implementation
*Helen Ayles, Zambart, Zambia
8:45
15 min
Panel discussion
*Rachel Baggaley, World Health Organization, Switzerland
*Siobhan Crowley, The Global Fund, Switzerland
*Helen Ayles, Zambart, Zambia
*David Serwadda, Makerere University, Uganda
*Sarah Fidler, Imperial College London, United Kingdom
*Richard Hayes, London School of Hygiene and Tropical Medicine, United Kingdom

Oral Abstract Session, OALBC01

11:45
2 min
Introduction
Ayesha Kharsany, CAPRISA, South Africa
11:47
8 min
High prevalence of asymptomatic Omicron carriage and correlation with CD4+ T cell count among adults with HIV enrolling in COVPN 3008 Ubuntu clinical trial in sub-Saharan Africa
*Jessica Andriesen, Fred Hutchinson Cancer Center, United States
11:55
8 min
A phase IV open-label evaluation of valuation of safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to HIV-1
Lijun Sun, Beijing Youan Hospital, Capital Medical University, China
12:03
8 min
National roll out of community HIV screening among key populations in Indonesia: assessment of early results
Budi Utomo, Universitas Indonesia, Indonesia
12:11
8 min
Predictors of high viral load among adult HIV recipients of care in Zambia, 2021: a cross-sectional analysis of HIV case-based surveillance data
Sulani Nyimbili, Centre for Infectious Diseases Research, Zambia
12:19
26 min
Q&A
Ayesha Kharsany, CAPRISA, South Africa
Lijun Sun, Beijing Youan Hospital, Capital Medical University, China
Sulani Nyimbili, Centre for Infectious Diseases Research, Zambia
Budi Utomo, Universitas Indonesia, Indonesia
*Jessica Andriesen, Fred Hutchinson Cancer Center, United States

Poster Exhibition and E-Posters

Associated Protocols Abstract Title Presenter Format
HVTN 702 EPLBA02: Analysis of the HVTN 702 Phase 2b-3 HIV-1 vaccine trial in South Africa assessing RV144 antibody and T-cell correlates of HIV-1 acquisition risk Zoe Moodie E-poster
HVTN 705 EPA007: Immune correlates of cell-associated HIV RNA levels in infected individuals undergoing long-term antiretroviral therapy Chuen-Yen Lau E-poster
HVTN 127 /HVTN 130 PESUA14: Administration of the broadly neutralizing, CD4-binding site targeting antibody VRC07-523LS in dual- and triple-antibody combinations with 10-1074, PGT121, and/or PGDM1400: impact on pharmacokinetics compared to VRC07-523LS administration alone Stephen Walsh Poster exhibition
HVTN 136 PELBA02: First-in-human evaluation of safety and pharmacokinetics of intravenous or subcutaneous infusions of PGT121.141.LS, an anti-V3 HIV-1 broadly neutralizing monoclonal antibody in healthy volunteers without HIV Srilatha Edupuganti E-poster
IMPAACT 2015 PESUA19: High prevalence of HIV persistence in CSF of adolescents and young adults with perinatally-acquired HIV and cognitive impairment in the IMPAACT 2015 study Ann Chahroudi Poster exhibition

Associated Protocols Abstract Title Presenting Author Format
HVTN 805 /HPTN 093 EPLBB08: Analytical Treatment Interruption (ATI) Among African Women with Early ART Initiation with or without VRC01 Circulating at HIV Acquisition: Study Design and Early Observations of Viral Rebound and Control  Shelly Karuna E-poster
IMPAACT 2002 EPB222: Participant Acceptability and Clinician Satisfaction of Cognitive Behavioral Therapy and a Medication Management Algorithm Compared with Enhanced Standard Care for Treatment of Depression among Youth Living with HIV Lauren Bergam E-poster
IMPAACT 2017 PEMOB29: Selection of Cabotegravir Dosing Regimens for HIV Treatment and Pre-exposure Prophylaxis (PrEP) in Adolescents by Leveraging Adult Data Mark Baker Poster exhibition

Associated Protocols Abstract Title Presenting Author Format
HVTN 071 PEMOC36: The effect of universal testing and treatment for HIV on health-related quality of life – data from the HPTN 071 (PopART) cluster randomised trial in Zambia and South Africa Katherine Davis Poster Exhibition
HPTN 083 EPLBC04: Transgender Women (TGW) in HPTN 083: An Evaluation of Safety, Efficacy, and Gender Affirming Hormonal Therapy (GAHT) Interactions with Long-acting Cabotegravir (CAB-LA) Beatriz Grinsztejn E-poster
HPTN Modelling Centre EPC150: Population-Level Impact of Expanding PrEP Coverage Among Men Who Have Sex with Men with Long-Acting Injectable Cabotegravir: Model Comparison Analysis for Atlanta, U.S. and Montreal, Canada Sarah Stansfield E-poster

Associated Protocols Abstract Title Presenting Author Format
HPTN 068 EPD151: Trajectories of Depressive Symptoms and HIV-Related Sexual Behaviors Among Adolescent Girls and Young Women in Rural South Africa (HPTN 068) Nivedita Bhushan E-poster
HPTN 068 EPD158: Effects of Quality of Caregiver-Adolescent Relationship on HIV, HSV-2 and on Pregnancy Incidence Among Young Women in Rural South Africa Enrolled in HPTN 068 Nosipho Shangase E-poster
HPTN 071 EPD028: Mobility and HIV Transmission Across Three Urban Communities in Zambia: Using Qualitative Data to Interpret Phylogenetics in a Mixed Methods Analysis of HPTN 071 (PopART) Data Melvin Simuyaba E-poster
HPTN 082 EPD339: Motivations for Starting, Stopping and Restarting Oral PrEP: Experiences of Adolescent Girls and Young Women in the HPTN 082 Trial Lisa Mills E-poster
HPTN 084 EPD103: Acceptability of Injectable Cabotegravir Versus Daily Oral TDF/FTC for PrEP: Lesson from HPTN 084 Nomhle Khoza E-poster
HVTN 706 EPD004: Utilizing standardized metrics to track recruitment strategies in a global preventive HIV vaccine study during the COVID-19 pandemic Rafael Gonzalez E-poster

Associated Protocols Abstract Title Presenting Author Format
N/A EPE331: The Representative Studies Rubric: 12 steps to address underrepresentation in HIV clinical research Brian Minalga E-poster

Global Village Exhibition Booths